<DOC>
	<DOCNO>NCT00677469</DOCNO>
	<brief_summary>The enterohepatic circulation thyroid hormone increase thyrotoxicosis.Bile-salt sequestrants ( ionic exchange resin ) bind thyroid hormone intestine thereby increase fecal excretion . Based observation , use cholestyramine try . The present study evaluate effect low dos cholestyramine adjunctive therapy management hyperthyroidism</brief_summary>
	<brief_title>Low Doses Cholestyramine Treatment Hyperthyroidism</brief_title>
	<detailed_description>The gastrointestinal tract role thyroid physiology . Thyroid hormone metabolize mainly liver , conjugate glucurunides sulfate . These conjugation product excrete bile . Free hormone release intestine finally reabsorb , complete enterohepatic circulation thyroid hormone . A small portion daily production thyroxin ( T4 ) triiodothyronine ( T3 ) , less 10 percent , excrete stool ( 1-3 ) . In people normal thyroid function , pathway T4 T3 recirculation contribute little hormone availability patient gastrointestinal disease receive drug decrease T4 absorption abnormal thyroid function ( 4 ) . However , thyrotoxic state characterize increase enterohepatic circulation thyroid hormone , well increased urinary fecal excretion conjugate free T4 ( 5,6 ) . Cholestyramine , ionic exchange resin sequesters T4 intestine increase fecal excretion . These phenomenon prove hamster mid 1960s ( 7 ) . Experimentally , show 50 mg cholestyramine bind approximately 3000 Î¼g T4 ( 8 ) therefore enhance clearance thyroid hormone . Because increase enterohepatic circulation thyroid hormone hyperthyroidism , attempt make sequester hormone intestine use ionic exchange resin ( 9-13 ) . Cholestyramine therapy study treatment thyrotoxicosis adjunctive therapy thionamides , find decrease thyroid hormone level rapidly . In several trial , cholestyramine combination methimazole ( MMI ) propylthiouracil , cause rapid decline thyroid hormone level standard therapy thionamides alone ( 9-11,13 ) . In trial , cholestyramine dose 4 gram orally two four time day . This study conduct examine efficacy combination therapy low dos cholestyramine MMI propranolol treat patient Graves ' hyperthyroidism .</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Hyperthyroidism</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<criteria>Patients newly diagnose hyperthyroid Graves ' disease If patient treat previously diabetes , kidney , liver disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Hyperthyroidism</keyword>
	<keyword>Cholestyramine</keyword>
</DOC>